Christopher German Biography and Net Worth



Christopher German is the CAO of Rhythm Pharmaceuticals. They are 53 years old.

What is Christopher Paul German's net worth?

The estimated net worth of Christopher Paul German is at least $123.05 thousand as of June 10th, 2025. German owns 1,889 shares of Rhythm Pharmaceuticals stock worth more than $123,049 as of July 9th. This net worth approximation does not reflect any other investments that German may own. Learn More about Christopher Paul German's net worth.

How old is Christopher Paul German?

German is currently 53 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who is 70 years old. Learn More on Christopher Paul German's age.

How do I contact Christopher Paul German?

The corporate mailing address for German and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Christopher Paul German's contact information.

Has Christopher Paul German been buying or selling shares of Rhythm Pharmaceuticals?

Christopher Paul German has not been actively trading shares of Rhythm Pharmaceuticals during the last ninety days. Most recently, Christopher Paul German sold 2,069 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $67.19, for a transaction totalling $139,016.11. Following the completion of the sale, the chief accounting officer now directly owns 1,889 shares of the company's stock, valued at $126,921.91. Learn More on Christopher Paul German's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Alastair Garfield (Chief Scientific Officer), Christopher German (CAO), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 34 times. They sold a total of 382,699 shares worth more than $21,548,140.82. The most recent insider tranaction occured on July, 2nd when insider Alastair Garfield sold 1,319 shares worth more than $85,484.39. Insiders at Rhythm Pharmaceuticals own 6.1% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 7/2/2025.

Christopher Paul German Insider Trading History at Rhythm Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2025Sell2,069$67.19$139,016.111,889View SEC Filing Icon  
3/21/2025Sell344$54.23$18,655.122,889View SEC Filing Icon  
2/19/2025Sell635$57.22$36,334.702,070View SEC Filing Icon  
4/2/2024Sell368$41.76$15,367.68795View SEC Filing Icon  
See Full Table

Christopher Paul German Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows Christopher Paul German's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $65.14
Low: $64.65
High: $67.17

50 Day Range

MA: $62.90
Low: $56.79
High: $68.11

2 Week Range

Now: $65.14
Low: $40.61
High: $73.33

Volume

552,607 shs

Average Volume

558,209 shs

Market Capitalization

$4.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26